DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamano, K.
Right arrow Articles by Iga, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamano, K.
Right arrow Articles by Iga, T.

Vol. 27, Issue 11, 1225-1231, November 1999

Correlation between In Vivo and In Vitro Hepatic Uptake of Metabolic Inhibitors of Cytochrome P-450 in Rats

Katsuhiro Yamano, Koujirou Yamamoto, Hajime Kotaki, Sayuri Takedomi, Hirotami Matsuo, Yasufumi Sawada, and Tatsuji Iga

Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan (Ka.Y., T.I.); Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima, Yodogawa-ku, Osaka, Japan (Ka.Y.); Department of Clinical Pharmacology School of Medicine, Gunma University, Showa-machi, Maebashi, Japan (Ko.Y.); Department of Pharmacy, The Research Hospital, The Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan (H.K.); Faculty of Pharmaceutical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan (S.T., H.M., Y.S.)

To predict the degree of accumulation of hepatic metabolic inhibitors in the liver from the in vitro data, we investigated the relationship between cell/medium concentration ratios (C/M ratios) in isolated rat hepatocytes and liver/blood unbound concentration (KBf) after i.v. administration of various metabolic inhibitors such as itraconazole, ketoconazole, verapamil, diltiazem, enoxacin, ciprofloxacin, clarithromycin, cimetidine, and nizatidine. The C/M ratios of itraconazole were ~6000 and 200 at the concentrations of 0.1 and 10 µg/ml, respectively, and the uptake of ketoconazole and verapamil into the hepatocytes also showed a concentration dependence, although the degree was smaller than that of itraconazole. The uptake of diltiazem, enoxacin, ciprofloxacin, and clarithromycin into the hepatocytes showed linear profiles on concentration dependence. There was an excellent correlation between C/M ratios and KBf values of all nine drugs with a slope of 1. This finding suggested the possibility of predicting drug concentrations in the liver (CH) from C/M ratios, the blood concentrations of drugs (CB) and unbound fraction in blood (fB), which was expressed by CH = (C/M) · CB · fB. It may be possible to predict the drug concentrations in human liver from KBf values estimated with isolated human hepatocytes and concentrations in the blood in a similar manner as in rats.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
K. A Bachmann and J. D Lewis
Predicting Inhibitory Drug-Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants
Ann. Pharmacother., June 1, 2005; 39(6): 1064 - 1072.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. M. Jones, D. Hallifax, and J. B. Houston
QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES
Drug Metab. Dispos., May 1, 2004; 32(5): 572 - 580.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al.
Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone
J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Kotegawa, B. E. Laurijssens, L. L. von Moltke, M. M. Cotreau, M. D. Perloff, K. Venkatakrishnan, J. S. Warrington, B. W. Granda, J. S. Harmatz, and D. J. Greenblatt
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1228 - 1237.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Skov, K.M. Main, I.B. Sillesen, J. Muller, C. Koch, and S. Lanng
Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide
Eur. Respir. J., July 1, 2002; 20(1): 127 - 133.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.